Daily News — May 1, 2026
About this episode
In this episode: Ineffable Intelligence emerges from stealth with a record-breaking $1.1B seed to build autonomous reinforcement learning systems. Synaps raises €3.06M pre-seed for an AI canvas for architects. Tapaya brings in-person payments directly into apps with €1M pre-seed. VNYX automates resale of returns and overstock in fashion with €1M+. Decameal turns invasive crabs into protein ingredients for the feed industry. BioOrbit raises £9.8M to manufacture cancer drugs in microgravity. Closing: Earlybird closes €360M Fund VIII and KOMPAS VC closes €160M Fund II.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Startups mentioned
Ineffable Intelligence
Ineffable Intelligence is a UK frontier AI lab incorporated in 2025 and emerging from stealth in 2026 with a $1.1B seed round at a $5.1B valuation. The company is working on reinforcement-learning-based superlearners: systems designed to generate new knowledge through interaction, simulation and experience.
Synaps
Synaps is an Austrian startup bringing generative AI to architecture. Its canvas platform lets architects and designers design, visualize, collaborate and present in a single environment, aiming to challenge traditional tools like AutoCAD.
Tapaya
Tapaya is a Czech startup that raised €1M pre-seed in 2026 to build embedded in-person payment infrastructure. The platform allows banks, fintechs and vertical software to integrate payment acceptance directly into their applications, reducing dependency on dedicated physical terminals.
VNYX
VNYX is a Dutch startup that raised €1M+ in 2026 to automate sustainable fashion resale. The platform combines AI, software and proprietary hardware to process returns, overstock and second-hand items, reducing processing time from 19 to 3 minutes per item.
Decameal
Decameal is a Danish startup that raised a seed round in 2026 to transform invasive crabs into sustainable ingredients for the feed industry. Its patent-pending process converts an environmental problem into a new protein and lipid supply chain for aquaculture and animal farming.
BioOrbit
BioOrbit is a British startup that raised £9.8M seed in 2026 to manufacture cancer drugs in space. It develops an autonomous unit called BOX that uses microgravity to crystallize anti-cancer antibodies in purer form, potentially enabling subcutaneous administration formulations.